Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,022 | 0,034 | 22:03 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.07. | Stagezero Life Sciences Ltd (2): Stagezero to delist from TSX, applies for NEX listing | 2 | Stockwatch | ||
25.07. | StageZero Life Sciences Ltd.: StageZero Announces Delisting from the TSX and a Concomitant Application for Listing on the NEX Exchange | 1 | TheNewswire | ||
STAGEZERO LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
14.05. | Stagezero Life Sciences Ltd (2): Stagezero, ElevationMD use Aristotle to detect cancer | 1 | Stockwatch | ||
13.05. | StageZero Life Sciences Ltd.: StageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of Cancer | 3 | TheNewswire | ||
07.05. | StageZero Life Sciences Ltd.: StageZero Announces Partial Revocation of Cease Trade Order and Proposed Financing | 4 | TheNewswire |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CARL ZEISS MEDITEC | 43,100 | -0,23 % | DORC-Power bei Carl Zeiss Meditec: Auftragseingang explodiert um 23,3 %, Aktie im Aufwind | Carl Zeiss Meditec steuert mit einem konsolidierten Umsatz von 1 600,1 Mio. € nach neun Monaten ein Wachstum von +7,6 % ein - währungsbereinigt immer noch +8,0 %. Organisch steigt der Umsatz leicht... ► Artikel lesen | |
INTUITIVE SURGICAL | 412,05 | +0,57 % | ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue? | ||
BOSTON SCIENTIFIC | 87,80 | -0,23 % | Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions | Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO Christopher Rowland (ex-Boston Scientific)... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,558 | -23,41 % | Plus Therapeutics files to sell 33M shares of common stock for holders | ||
MOUNTAIN VALLEY MD | 0,015 | +13,64 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
EMPOWER CLINICS | - | - | Empower Clinics Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
LIFEWARD | 0,709 | +1,58 % | Lifeward Ltd.: Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
SENSEONICS | 0,398 | -0,50 % | Senseonics Holdings, Inc. Reports Second Quarter Financial Results | Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
EKSO BIONICS | 3,190 | +9,62 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
IMUNON | 5,990 | +1,53 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
BIOCEPT | 7,200 | 0,00 % | GlaxoSmithKline Bioc: Gewinn im zweiten Quartal bei 5,9 Mio. EGP | ||
ROCKWELL MEDICAL | 0,853 | +2,03 % | Rockwell Medical Q2 Earnings Preview | ||
AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
MEMPHASYS | 0,001 | 0,00 % | MEMPHASYS LIMITED: Results of Meeting | ||
VIRIDIAN THERAPEUTICS | 15,145 | +5,65 % | These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results |